-
公开(公告)号：EP3280705A1
公开(公告)日：2018-02-14
申请号：EP16720354.6
申请日：2016-04-07
申请人： Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) , Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie
发明人： BRACK-WERNER, Ruth , HELFER, Markus , RÖSNER, Manfred , SCHNEIDER, Martha , PROTZER, Ulrike , HERTWECK, Christian , WERNEBURG, Martina
IPC分类号： C07D309/32 , A61K31/351 , C07D407/04 , A61P31/12 , A61P31/18
CPC分类号： C07D407/04 , A61K9/0053 , A61K31/351 , A61K45/06 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07D309/32 , A61K2300/00
摘要： The present invention relates to compounds and compositions for use in methods of treating and/or preventing conditions, disorders or diseases that are mediated or caused by a virus.
-
公开(公告)号：EP2958587A1
公开(公告)日：2015-12-30
申请号：EP14706057.8
申请日：2014-02-25
申请人： Klinikum rechts der Isar der Technischen Universität München , Technische Universität München , Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
IPC分类号： A61K39/39
CPC分类号： A61K39/292 , A61K39/39 , A61K2039/525 , C12N7/00 , C12N2730/10134 , C12N2730/10171
摘要： In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.
-
公开(公告)号：EP3402888B1
公开(公告)日：2020-08-26
申请号：EP17701067.5
申请日：2017-01-12
-
4.发明公开BI- OR MULTISPECIFIC POLYPEPTIDES BINDING IMMUNE EFFECTOR CELL SURFACE ANTIGENS AND HBV ANTIGENS FOR TREATING HBV INFECTIONS AND ASSOCIATED CONDITIONS 审中-公开BI或多特异性多肽免疫效应细胞表面抗原和HBV抗原用于治疗HBV感染和相关疾病约束力
公开(公告)号：EP3046938A1
公开(公告)日：2016-07-27
申请号：EP14771250.9
申请日：2014-09-16
申请人： Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) , Deutsches Krebsforschungszentrum
IPC分类号： C07K16/08 , C07K16/28 , C07K16/46 , A61K39/395 , A61P31/20
CPC分类号： C07K16/2809 , A61K2039/505 , A61K2039/507 , C07K16/082 , C07K16/2803 , C07K16/2818 , C07K16/283 , C07K2317/14 , C07K2317/31 , C07K2317/35 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2319/00 , C12N5/0638 , C12N5/0646
摘要： The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.
-
公开(公告)号：EP3402888A1
公开(公告)日：2018-11-21
申请号：EP17701067.5
申请日：2017-01-12
摘要： The present invention relates to an improved recombinant vaccination vector for the treatment or vaccination against hepatitis B virus (HBV) as well as pharmaceutical compositions or vaccines comprising said recombinant vaccination vector. The present invention also relates to a recombinant vaccination vector for use in a method of vaccination against HBV, as well as kits comprising a vaccine comprising the recombinant vaccination vector.
-
公开(公告)号：EP2958587B1
公开(公告)日：2018-11-21
申请号：EP14706057.8
申请日：2014-02-25
申请人： Klinikum rechts der Isar der Technischen Universität München , Technische Universität München , Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
IPC分类号： A61K39/39
CPC分类号： A61K39/292 , A61K39/39 , A61K2039/525 , C12N7/00 , C12N2730/10134 , C12N2730/10171
摘要： In a first aspect, the present invention relates to the use of a TLR 9 agonist and/or a TLR 4 agonist in a prophylactic or therapeutic vaccine. According to the present vaccination strategy, the TLR 9 agonist and/or TLR 4 agonist is adapted or designed for use as a multiplying jump agent to enhance numbers and functionality of CD8 T cells in a prime-jump vaccination strategy for jump T cell expansion. In particular, the TLR 9 agonist and/or TLR 4 agonist is used as a component to be administered after priming of the individual to be vaccinated. The vaccination strategy is particularly useful against acute and chronic infections with intracellular pathogens or for anti-tumor vaccination. In another aspect, the present invention relates to a kit of part containing a prime agent and a multiplying jump agent according to the present invention.
-
7.发明公开TRISPECIFIC BINDING MOLECULES FOR TREATING HBV INFECTION AND ASSOCIATED CONDITIONS 审中-公开用于治疗HBV感染的三特异性结合分子及相关病症
公开(公告)号：EP3271387A1
公开(公告)日：2018-01-24
申请号：EP16711223.4
申请日：2016-03-16
申请人： Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) , Deutsches Krebsforschungszentrum , Technische Universität München
CPC分类号： C07K16/082 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/283 , C07K16/2851 , C07K16/2878 , C07K16/468 , C07K2317/31 , C07K2317/35 , C07K2317/50 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2319/00
摘要： The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen; (b) (i) the second and third specificity are for CD3 and CD28, respectively; or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D; and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain; or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.024 秒)
